SCHEMBL18220219

SCHEMBL18220219

CCC(O)CNC(=O)/C(C#N)=C/c1ccc(-c2ccc3cc(N(CC)CC)ccc3c2)n1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 14/20 0.40
KMT2A Q03164 14/20 0.40
ALDH1A1 P00352 11/20 0.40
MAPK1 P28482 6/20 0.40
TDP1 Q9NUW8 4/20 0.40
L3MBTL1 Q9Y468 4/20 0.40
LMNA P02545 3/20 0.40
DNM1 Q05193 1/20 0.39
MAPT P10636 13/20 0.38
NPSR1 Q6W5P4 2/20 0.38
RAB9A P51151 3/20 0.37
NPC1 O15118 2/20 0.37
POLB P06746 3/20 0.35
USP2 O75604 5/20 0.33
KDM4E B2RXH2 4/20 0.33
HPGD P15428 2/20 0.33
HTT P42858 2/20 0.33
IDE P14735 1/20 0.33
RECQL P46063 2/20 0.32
BLM P54132 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18221395 0.95 MEN1 (0.39) MEN1KMT2AALDH1A1MAPK1TDP1
SCHEMBL18220212 0.93 DNM1 (0.38) MEN1KMT2AALDH1A1MAPK1TDP1
SCHEMBL18220225 0.93 DNM1 (0.39) MEN1KMT2AALDH1A1MAPK1TDP1
SCHEMBL17120800 0.88 DNM1 (0.37) MEN1KMT2AALDH1A1MAPK1TDP1
SCHEMBL18221404 0.86 DNM1 (0.39) MEN1KMT2AALDH1A1MAPK1TDP1
SCHEMBL18220185 0.85 LMNA (0.47) MEN1KMT2AALDH1A1MAPK1TDP1
SCHEMBL25610365 0.85 MEN1 (0.36) MEN1KMT2AALDH1A1MAPK1TDP1
SCHEMBL17120762 0.84 MEN1 (0.53) MEN1KMT2AALDH1A1MAPK1TDP1
SCHEMBL18220208 0.83 APP (0.40) MEN1KMT2AALDH1A1MAPK1TDP1
SCHEMBL18220213 0.83 APP (0.41) MEN1KMT2AALDH1A1MAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 MEN1 2997/4885KMT2A 4649/4885ALDH1A1 4151/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 MEN1 2997/4885KMT2A 4649/4885ALDH1A1 4151/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA MEN1 2973/4885KMT2A 4621/4885ALDH1A1 4226/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA MEN1 2973/4885KMT2A 4621/4885ALDH1A1 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.